[Adriamycin and autologous bone marrow transplantation. Preclinical studies in dogs (author's transl)].
We investigated the toxicity of adriamycin (ADM) in dogs with regard to autologous bone marrow transplantation (BMT). Gastrointestinal toxicity limited the dose of ADM in single administration (3.0 mg/kg) and chronic cardiotoxicity in repeated administration (9 X 1.5 mg/kg every two weeks). The recovery of hemopoiesis was complete within 25 days after single and repeated doses of ADM as indicated by the restoration of blood counts and concentration of hemopoietic precursors (CFUc) as well as proliferate activity of bone marrow. At this time bone marrow was obtained and reinfused after total body irradiation (TBI) with 10 Gy. Single and repeated doses of 1.5 mg/kg ADM did not delay recovery of blood counts after autologous BMT as compared to transplantation of untreated marrow - in contrast a single dose of 3.0 mg/kg ADM did. Our results indicate that toxicity of ADM is not influenced by autologous BMT. Previous shorter therapy with conventional doses of ADM does not preclude autologous BMT.
D000818:Animals; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects*; D016026:Bone Marrow Transplantation; D004285:Dogs; D004317:Doxorubicin / Q000494:pharmacology* / Q000633:toxicity; D006412:Hematopoietic Stem Cells; D013997:Time Factors; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation
D004317:Doxorubicin
Adriamycin und autologe Knochenmarktransplantation. Vorklinische Studien am Tiermodell (Hund)